FDA has announced it has expanded the approved use of Humira (adalimumab), manufactured by Abbott Laboratories, to include treatment of moderate-to-severe ulcerative colitis in adults, according to a ...

Celltrion USA is offering an 80 mg dose of Yuflyma (adalimumab-aaty), a high-concentration (100mg/ml) and citrate-free formulation of Humira (adalimumab) biosimilar, in the United States. Yuflyma is ...

Abbott has announced results from a post-hoc analysis of the 52-week Humira (adalimumab) ULTRA 2 study which showed that patients with moderately to severely active ulcerative colitis (UC) who failed, ...

Biologics in IBD: More Thoughtful Use Could Improve Outcomes The marketplace introduction of infliximab for the treatment of IBD did not reduce hospitalization or surgery rates in a large population ...